IBI3033
/ Innovent Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
May 27, 2026
A Mutiple-dose Study of IBI3033 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=8 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed
May 23, 2026
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • First-in-human
April 25, 2026
A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
March 10, 2026
A Mutiple-dose Study of IBI3033 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=8 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
New P1 trial
December 31, 2025
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
First-in-human • New P1 trial
1 to 5
Of
5
Go to page
1